Fig. 3From: Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironmentEffects of TIL expression and differences in progression type upon prognosis. In 19 cases, individuals with type I progression had significantly longer PFS compared to those with type III progression (p = 0.040, log-rank) (a). Furthermore, individuals with type I progression had significantly longer OS compared to those with type III and type II progression (p < 0.001 and p = 0.047, respectively; log-rank) (b)Back to article page